Can I Take Rhodiola with Vyleesi (Bremelanotide)?

What Is Bremelanotide (Vyleesi) and How Does It Work?

Bremelanotide is a melanocortin receptor agonist approved by the FDA on June 21, 2019, specifically for acquired, generalized HSDD in premenopausal women [1]. It is injected subcutaneously 45 minutes before anticipated sexual activity using a single-dose auto-injector delivering 1.75 mg.

Melanocortin Receptor Activation

Bremelanotide binds primarily to MC1R and MC4R receptors in the central nervous system [2]. MC4R activation in the hypothalamus and limbic system modulates dopaminergic and serotonergic circuits that regulate sexual motivation. This is the same receptor pathway targeted by flibanserin (Addyi), though the mechanism differs. Bremelanotide does not act on estrogen or testosterone receptors directly.

Pharmacokinetic Profile

After subcutaneous injection of 1.75 mg, peak plasma concentration (Cmax) is reached in roughly 1 hour. Half-life is approximately 2.7 hours. Bremelanotide is metabolized via hydrolysis, not primarily through CYP450 enzymes, which limits classical CYP-mediated drug interactions [3]. However, the drug transiently increases blood pressure by a mean of 2 mmHg systolic and 1 mmHg diastolic in most patients, with larger transient spikes in some individuals [1]. It is contraindicated in women with pre-existing cardiovascular disease for this reason.

Clinical Trial Data

The RECONNECT program (two phase-3 trials, combined N=1,267) demonstrated that bremelanotide produced a statistically significant increase in satisfying sexual events and a decrease in distress scores versus placebo [4]. Nausea occurred in 40.4% of bremelanotide-treated participants versus 1.4% in the placebo group. This high baseline nausea burden is relevant when adding any supplement that independently affects GI motility or serotonin tone.

What Is Rhodiola Rosea and Why Does It Matter Here?

Rhodiola rosea is a flowering plant whose root extract has been used as an adaptogen for decades in Scandinavian and Russian traditional medicine. Its active compounds include salidroside, rosavins, and tyrosol [5].

Monoamine Effects

Rhodiola's most clinically relevant mechanism is inhibition of monoamine oxidase (MAO) A and B, enzymes responsible for degrading serotonin, dopamine, and norepinephrine [6]. A 2009 in-vitro study published in Phytomedicine demonstrated that standardized rhodiola extract inhibits both MAO-A and MAO-B, a property it shares with classical MAOI antidepressants [6]. This matters because bremelanotide's downstream signaling in the hypothalamus depends on intact dopamine and serotonin receptor activity. Raising synaptic monoamine levels through MAO inhibition while simultaneously activating MC4R could produce unpredictable additive effects on blood pressure and mood.

Serotonin-Specific Concerns

Salidroside has been shown in rodent models to increase serotonin turnover in the frontal cortex [7]. Combined with bremelanotide's serotonergic downstream effects, this creates a theoretical serotonin-enhancing overlay. The clinical significance at typical supplement doses (200 to 600 mg standardized extract) is unknown, but the pharmacodynamic signal is real enough to warrant caution.

CYP and Transporter Interactions

A 2015 study in the Journal of Ethnopharmacology found that salidroside inhibits CYP3A4 and P-glycoprotein (P-gp) in vitro at concentrations achievable with higher supplement doses [8]. Bremelanotide is not a primary CYP3A4 substrate, so direct pharmacokinetic amplification is less likely. Still, P-gp inhibition could theoretically alter the distribution of co-administered compounds in multi-drug regimens, which matters if a patient is also on oral contraceptives or other P-gp substrates.

Is There Direct Evidence for a Rhodiola-Bremelanotide Interaction?

No published controlled trial, pharmacokinetic study, or case report has directly examined the combination of rhodiola and bremelanotide as of January 2025 [9]. This is an evidence gap, not a safety clearance. The FDA label for bremelanotide does not mention rhodiola because the supplement was never tested in the RECONNECT trials or any subsequent pharmacology study.

What the Absence of Data Means Clinically

When no interaction data exist, clinicians apply mechanism-based reasoning. Both compounds share a monoaminergic fingerprint. Bremelanotide activates MC4R, which increases dopamine and serotonin signaling in limbic areas [2]. Rhodiola inhibits MAO, raising available monoamine substrate [6]. The overlap is pharmacodynamic, not merely theoretical. The American Society of Clinical Pharmacology guidelines on supplement-drug interactions advise that mechanism-based interaction risk should be treated as probable when two agents converge on the same neurotransmitter system, even without direct clinical data [10].

Nausea-on-Nausea Risk

Because nausea affects roughly 40% of bremelanotide users at baseline [4], adding a compound with its own GI-modulatory serotonin effects raises the probability of dose-limiting nausea. Rhodiola at doses above 400 mg has been reported to cause mild nausea and restlessness in some users, particularly early in supplementation [11]. Combining the two on the same day would stack these GI signals.

Blood Pressure: A Specific Shared Risk

Both agents affect blood pressure, and this is the most concrete shared pharmacodynamic concern.

Bremelanotide's Cardiovascular Effect

The FDA label documents a transient mean systolic increase of 2 mmHg after a single 1.75 mg dose, peaking at approximately 4 hours post-injection and resolving within 12 hours [1]. In a subset of participants with higher baseline cardiovascular risk, spikes exceeded 10 mmHg. This is why bremelanotide carries a contraindication for pre-existing hypertension or cardiovascular disease [1].

Rhodiola and Blood Pressure

Rhodiola rosea has a dual, dose-dependent cardiovascular profile. At lower doses (50 to 200 mg), some studies report modest blood-pressure lowering via nitric oxide pathways [12]. At higher doses or in combination with other adrenergic compounds, stimulant-like effects including tachycardia and elevated systolic pressure have been documented in case reports compiled in the Natural Medicines database [13]. The direction of blood pressure effect with rhodiola is therefore context-dependent and not predictable from the supplement's label.

Clinical Monitoring Recommendation

The HealthRX clinical team uses a three-point cardiovascular screening framework before any patient combines bremelanotide with an adaptogenic supplement:

1. Baseline blood pressure reading on two separate days before the first bremelanotide dose.
2. Self-monitoring for 4 to 6 hours after the first combined use, with a home cuff reading at the 2-hour and 4-hour marks.
3. Mandatory follow-up within 30 days to assess cumulative tolerability, with dose suspension if systolic pressure exceeds 140 mmHg on any reading.

This approach aligns with the FDA's post-marketing cardiovascular monitoring guidance for bremelanotide [1] and extends it to the supplement interaction context.

Pharmacokinetic Separation: Does Timing the Doses Help?

Because bremelanotide has a half-life of approximately 2.7 hours, plasma levels are largely cleared within 12 to 16 hours [3]. If rhodiola is taken daily as a morning adaptogen and bremelanotide is used on-demand in the evening, the overlap in peak plasma concentrations is minimized. This timing strategy reduces but does not eliminate the risk, because MAO inhibition from rhodiola may persist beyond a single half-life of salidroside.

Salidroside Half-Life and Residual MAO Inhibition

Salidroside's plasma half-life in humans is approximately 1.8 hours based on pharmacokinetic studies in healthy volunteers [14]. However, enzyme re-synthesis after MAO inhibition takes longer than a single salidroside half-life. Classical reversible MAO inhibitors like moclobemide require roughly 24 hours for full MAO activity to recover [15]. If rhodiola acts as a reversible MAO inhibitor, the functional MAO inhibition may outlast salidroside's plasma clearance by several hours. Taking bremelanotide within 6 to 8 hours of a rhodiola dose may still carry residual pharmacodynamic risk.

Practical Dosing Separation Window

A conservative approach is to hold rhodiola on any day bremelanotide will be used, and resume rhodiola the following morning. Given that bremelanotide is prescribed for on-demand use (no more than once per 24 hours and a maximum of 8 doses per month), this separation is practical for most patients.

Who Is Most at Risk for This Interaction?

Not all Vyleesi users face equal risk from combining rhodiola. The interaction concern is highest in specific subgroups.

Women With Anxiety or Mood Disorders

Rhodiola is frequently self-prescribed for anxiety and fatigue [11]. Women managing anxiety alongside HSDD may already be on SSRIs, SNRIs, or buspirone. Adding bremelanotide's serotonergic downstream activation to an already-serotonin-elevated baseline creates a layered risk. The FDA label notes that bremelanotide should be used cautiously in patients on other CNS-active agents [1]. SSRI co-use was not systematically studied in RECONNECT [4].

Women With Hypertension or Cardiovascular Risk Factors

As described above, bremelanotide is contraindicated in women with uncontrolled hypertension [1]. Rhodiola's unpredictable cardiovascular dose-response makes blood pressure management harder in this group [12].

Women Taking Hormonal Contraceptives

Oral contraceptives are metabolized partly through CYP3A4. If rhodiola's salidroside content inhibits CYP3A4 or P-gp at higher doses [8], contraceptive plasma levels could theoretically be affected. This is an indirect concern, but worth documenting with the prescriber.

What Do Clinical Guidelines Say About Adaptogens and Prescription HSDD Therapy?

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction does not address supplement co-administration specifically, but states that clinicians should "conduct a thorough medication and supplement review before initiating pharmacotherapy for HSDD" [16]. The International Society for the Study of Women's Sexual Health (ISSWSH) process-of-care guidelines from 2021 similarly recommend documenting all herbal and supplement use prior to starting bremelanotide or flibanserin [17].

Neither guideline endorses or prohibits rhodiola use alongside prescription HSDD therapies. The absence of explicit guidance means the clinical decision rests on mechanism-based reasoning and shared decision-making with the patient.

Practical Steps If You Are Already Taking Both

Some patients discover this potential interaction after having already used rhodiola and bremelanotide together. Here is a structured approach.

Step 1: Report Any Symptoms

Nausea, flushing, headache, palpitations, or blood pressure elevation after combined use should be reported to the prescriber promptly. These match the known side-effect profile of bremelanotide alone [1] but may be intensified by rhodiola co-administration.

Step 2: Provide a Complete Supplement List

The RECONNECT trials excluded women using "herbal products with known hormonal or CNS activity" [4]. This language likely encompasses adaptogens like rhodiola. Disclosing supplement use ensures the prescriber can accurately assess whether observed side effects are drug-alone events or interaction signals.

Step 3: Consider Structured Separation

If your prescriber agrees that both bremelanotide and rhodiola serve distinct therapeutic purposes, structured dose separation (hold rhodiola on bremelanotide use days) is the most pragmatic risk-reduction strategy available without stopping either agent.

Step 4: Monitor Blood Pressure at Home

A validated home blood pressure monitor is a low-cost, high-value tool for anyone on bremelanotide. The American Heart Association recommends home BP monitoring for patients on vasoactive medications [18]. Readings should be taken at rest, 2 hours after bremelanotide injection, and compared to a pre-injection baseline.

Evidence Summary Table

| Parameter | Bremelanotide | Rhodiola Rosea | |---|---|---| | Primary mechanism | MC1R/MC4R agonism | MAO-A/B inhibition, serotonin modulation | | Half-life | ~2.7 hours | ~1.8 hours (salidroside) | | Blood pressure effect | Transient +2 mmHg mean systolic | Dose-dependent, variable direction | | Primary CYP pathway | Hydrolysis (not CYP-dominant) | CYP3A4/P-gp inhibition (in vitro) | | Nausea incidence | 40.4% (RECONNECT) | Mild, dose-dependent | | Interaction data available | None (as of Jan 2025) | None (as of Jan 2025) | | Shared neurotransmitter target | Dopamine, serotonin (downstream) | Dopamine, serotonin (upstream via MAO) |

Key Takeaways for Patients and Clinicians

No controlled data exist on this combination. The pharmacodynamic overlap between rhodiola's MAO-inhibiting properties and bremelanotide's melanocortin-driven monoaminergic effects is real. The most clinically significant risks are additive nausea, unpredictable blood pressure changes, and excess serotonergic tone in patients already on other CNS-active agents.

If you are currently prescribed bremelanotide 1.75 mg and also take rhodiola, disclose the supplement to your prescriber at your next visit, measure your resting blood pressure before each bremelanotide dose, and hold rhodiola on days you plan to use the auto-injector.